Novo Nordisk’s nearly $1,000 per month diabetes medication Ozempic can be produced for less than $5 a month, according to a new study.
Researchers at Yale University, King’s College Hospital in London, and Doctors Without Borders found that the cost to manufacture a month’s supply of Ozempic — including with a profit margin— is between $0.89 to $4.74.
The study’s authors wrote that the findings suggest that Ozempic and other diabetes medications “can likely be manufactured for prices far below current prices, enabling wider access.”
For comparison, Ozempic’s current list price is $935.77 for four weekly injections. Although the list price doesn’t reflect what customer’s pay after available rebates are applied, that is still an almost 20,000% markup.
“While we are unaware of the analysis used in the study, we have always recognized the need for continuous evaluation of innovation and affordability levers to support greater access of our products,” Novo Nordisk told Quartz in an emailed statement.
Ozempic is a member of class of drugs known as GLP-1 agonists that help regulate blood sugar levels by triggering the pancreas to release more insulin. The medication has also become known for its weight loss side effects. Demand for Ozempic, along with Novo Nordisk’s weight loss drug Wegovy, has skyrocketed in the last year.
The company reported in January that its 2023 sales jumped 31% to 232.3 billion Danish kroner ($33.8 billion), compared with 177 billion Danish kroner ($25 billion) in 2022. It also projects sales will increase by up to 26% in 2024.
“Novo must substantially reduce the price of Ozempic in the U.S. now,” U.S. Sen. Bernie Sanders wrote in post on X in response to the study’s findings.
There is no rational reason, other than greed, for Novo Nordisk to charge Americans nearly $1,000 a month for Ozempic when it costs less than $5 to manufacture it and can be purchased in Germany for just $59. Novo must substantially reduce the price of Ozempic in the US now. pic.twitter.com/rdyF5MCQbX
— Bernie Sanders (@SenSanders) March 27, 2024
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
